posted 11/01/02
Bristol-Myers Squibb Company today announced that the U.S. Food
and Drug Administration (FDA) has approved Metaglip™ (glipizide and metformin
HCl Tablets) for use, along with diet and exercise, as initial drug therapy for
people with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed
with diet and exercise alone.
Metaglip™ was also approved as second-line
therapy for patients with type 2 diabetes who are currently taking either
metformin or a sulfonylurea with a regimen of diet and exercise, but whose blood
sugar levels are inadequately controlled. Metaglip combines glipizide and
metformin HCl -- two widely prescribed oral antidiabetic agents -- in a single
pill. These agents work in complementary fashion to improve blood sugar in
patients with type 2 diabetes.
In clinical trials, Metaglip was shown to be more
effective at lowering blood sugar levels than either glipizide or metformin used
alone in patients with type 2 diabetes.
Metaglip™ (glipizide and metformin HCl tablets)
will be available in three dosage strengths, including 2.5 milligram/250
milligram (mg) (glipizide/metformin HCl) tablets, 2.5 mg/500 mg tablets, and 5
mg/500 mg tablets.
Source: Diabetes In Control Dot Com.
Home - Table of Contents - Donate Now - About Diabetes - Warning Signs - Complications - Screening Test - Diabetes Terms - Site Search - Meet Mr. Diabetes® - Wake Up And Walk® Tour - Latest News - Headlines & News Stories - Health & Fitness - About Us - FAQ - Research Form - - Message Board - Privacy Policy - Legal Notices - How to Contact Us - Comments form - Suggestion Form - Our E-Mail Addresses - Our Address and Phone Numbers - Links - Contact Us